{"id":50814,"date":"2025-12-15T20:26:05","date_gmt":"2025-12-15T12:26:05","guid":{"rendered":"https:\/\/flcube.com\/?p=50814"},"modified":"2025-12-15T20:26:07","modified_gmt":"2025-12-15T12:26:07","slug":"huadao-submits-china-car-t-application-for-refractory-lymphoma-in-1b-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50814","title":{"rendered":"Huadao Submits China CAR\u2011T Application for Refractory Lymphoma in $1B Market"},"content":{"rendered":"\n

Suzhou Huadao Biological Pharmacy Co., Ltd.<\/strong> officially submitted a Marketing Authorization Application (MAA) to the Center for Drug Evaluation (CDE) of China\u2019s National Medical Products Administration (NMPA) for its first CAR\u2011T cell therapy, presumed to be HD CD19 CAR\u2011T<\/strong>, for the treatment of refractory and relapsed Non\u2011Hodgkin Lymphoma (r\/r NHL)<\/strong>. The therapy has also received clinical approval for B\u2011cell Acute Lymphoblastic Leukemia (B\u2011ALL)<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Submission Date<\/strong><\/td>15\u202fDec\u202f2025<\/td><\/tr>
Agency<\/strong><\/td>CDE\/NMPA (China)<\/td><\/tr>
Product<\/strong><\/td>HD CD19 CAR\u2011T (presumed name pending disclosure)<\/td><\/tr>
Primary Indication<\/strong><\/td>Refractory\/relapsed Non\u2011Hodgkin Lymphoma (r\/r NHL)<\/td><\/tr>
Secondary Indication<\/strong><\/td>B\u2011cell Acute Lymphoblastic Leukemia (B\u2011ALL)<\/td><\/tr>
Drug Class<\/strong><\/td>Autologous CAR\u2011T cell therapy<\/td><\/tr>
Innovation<\/strong><\/td>First CAR\u2011T submission from Suzhou Huadao<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>Details<\/th><\/tr><\/thead>
Technology<\/strong><\/td>Autologous T cells transduced with replication\u2011defective lentivirus<\/td><\/tr>
Target<\/strong><\/td>CD19 antigen on B\u2011cell malignancies<\/td><\/tr>
Mechanism<\/strong><\/td>Engineered CAR\u2011T cells recognize and kill CD19\u2011positive tumor cells<\/td><\/tr>
Manufacturing<\/strong><\/td>Lentiviral vector\u2011mediated gene transfer<\/td><\/tr>
Clinical Status<\/strong><\/td>MAA submitted for r\/r NHL; B\u2011ALL indication also approved in trials<\/td><\/tr>
Development Stage<\/strong><\/td>Registration filing (Phase 3 data completed)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Implication<\/th><\/tr><\/thead>
China NHL Incidence<\/strong><\/td>~75,000 new cases annually (2024)<\/td>~20\u201125% become r\/r, eligible for CAR\u2011T<\/td><\/tr>
China r\/r NHL Patients<\/strong><\/td>15,000\u201120,000 eligible for CAR\u2011T therapy annually<\/td>High unmet need post\u2011chemo\/immunotherapy<\/td><\/tr>
China CAR\u2011T Market<\/strong><\/td>\u00a52\u20113\u202fbillion (\u2248\u202fUS$280\u2011420\u202fM) (2025)<\/td>Dominated by Yescarta (Fosun Kite) and Carteyva (JW Therapeutics)<\/td><\/tr>
Peak Sales Forecast<\/strong><\/td>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> (\u2248\u202fUS$112\u2011170\u202fM) by 2030<\/td>15\u201120% market share with competitive pricing<\/td><\/tr>
Reimbursement Path<\/strong><\/td>Target NRDL inclusion by 2027 to accelerate adoption<\/td>Pricing pressure from existing competitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n